Repros Therapeutics (RPRX) Tops Q3 EPS by 7c

Repros Therapeutics (NASDAQ: RPRX) reported Q3 EPS of ($0.32), $0.07 better than the analyst estimate of ($0.39).

For earnings history and earnings-related data on Repros Therapeutics (RPRX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus